ATE466592T1 - Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten - Google Patents

Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten

Info

Publication number
ATE466592T1
ATE466592T1 AT01967517T AT01967517T ATE466592T1 AT E466592 T1 ATE466592 T1 AT E466592T1 AT 01967517 T AT01967517 T AT 01967517T AT 01967517 T AT01967517 T AT 01967517T AT E466592 T1 ATE466592 T1 AT E466592T1
Authority
AT
Austria
Prior art keywords
glp
conjunction
therapeutic agent
another therapeutic
bone diseases
Prior art date
Application number
AT01967517T
Other languages
English (en)
Inventor
Dennis Henriksen
Original Assignee
Sanos Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0022844A external-priority patent/GB0022844D0/en
Priority claimed from GB0029920A external-priority patent/GB0029920D0/en
Application filed by Sanos Bioscience As filed Critical Sanos Bioscience As
Application granted granted Critical
Publication of ATE466592T1 publication Critical patent/ATE466592T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01967517T 2000-09-18 2001-09-18 Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten ATE466592T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0022844A GB0022844D0 (en) 2000-09-18 2000-09-18 Use of GLP-1 and GLP-2 peptides
GB0029920A GB0029920D0 (en) 2000-12-07 2000-12-07 Use of glp-1 and glp-2 peptides
PCT/GB2001/004178 WO2002024214A2 (en) 2000-09-18 2001-09-18 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders

Publications (1)

Publication Number Publication Date
ATE466592T1 true ATE466592T1 (de) 2010-05-15

Family

ID=26245018

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01982302T ATE396738T1 (de) 2000-09-18 2001-09-17 Verwendung von glp-2-peptiden
AT01967517T ATE466592T1 (de) 2000-09-18 2001-09-18 Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01982302T ATE396738T1 (de) 2000-09-18 2001-09-17 Verwendung von glp-2-peptiden

Country Status (11)

Country Link
US (2) US6770620B2 (de)
EP (3) EP1326630B1 (de)
JP (2) JP5161412B2 (de)
AT (2) ATE396738T1 (de)
AU (2) AU2002213925A1 (de)
CY (2) CY1108263T1 (de)
DE (2) DE60134251D1 (de)
DK (2) DK1326630T3 (de)
ES (2) ES2310192T3 (de)
PT (2) PT1326630E (de)
WO (2) WO2002022151A2 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002022151A2 (en) * 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
RO120121B1 (ro) * 2000-12-18 2005-09-30 Elena Ionaşcu Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
DE10135315A1 (de) * 2001-07-19 2003-01-30 Bayer Ag Stents
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
MXPA04011203A (es) * 2002-05-17 2005-07-14 Univ Duke Metodo para tratar la obesidad.
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1870096A3 (de) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Zusammensetzungen zur Beeinflussung von Gewichtsverlust
CN1822851B (zh) 2003-05-15 2011-04-13 塔夫茨大学信托人 肽和多肽药物的稳定类似物
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1734955A2 (de) * 2004-01-13 2006-12-27 Duke University Zusammensetzungen eines antikonvulsiven mittels und eines antipsychotischen mittels zur beeinflussung des gewichtsverlustes
EP1748776A1 (de) * 2004-05-03 2007-02-07 Duke University Zusammensetzungen zur beeinflussung des gewichtsverlusts
MX2007013431A (es) * 2005-05-04 2008-01-18 Zealand Pharma As Analogos del peptido 2 semejante al glucagon.
WO2006135660A2 (en) * 2005-06-10 2006-12-21 University Of Chicago Therapies involving lymphotoxin beta receptor
ES2761812T3 (es) * 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2007133747A2 (en) * 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
WO2009033746A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2898900B1 (de) 2008-09-19 2017-11-15 Nektar Therapeutics Polymerkonjugate von Ziconotid
EP2337585A1 (de) * 2008-09-19 2011-06-29 Nektar Therapeutics Polymerkonjugate von glp-2-artigen peptiden
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
EP2480246A4 (de) 2009-09-23 2013-02-27 Biokier Inc Zusammensetzung und verfahren zur behandlung von diabetes
EP2311486A1 (de) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103889457A (zh) * 2011-05-24 2014-06-25 波利威乐赞助有限公司 使用特异性的基于壳聚糖的纳米复合物用于有效并安全递送siRNA的组合物和方法
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TR201802689T4 (tr) 2012-05-03 2018-03-21 Zealand Pharma As Glukagon benzeri peptit-2 (glp-2) analogları.
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
US10493042B2 (en) 2013-08-01 2019-12-03 University-Industry Cooperation Group Of Kyung Hee University Method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent
WO2015016682A1 (ko) 2013-08-01 2015-02-05 경희대학교 산학협력단 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
WO2018009778A1 (en) * 2016-07-07 2018-01-11 Baylor College Of Medicine Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
WO2018069442A1 (en) 2016-10-12 2018-04-19 University Of Copenhagen Peptide dual agonists of gipr and glp2r
SG10201911851VA (en) 2016-12-09 2020-02-27 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
CA3090767A1 (en) * 2017-02-27 2018-08-30 Urigen N.A. Treatment of lower urinary tract epithelium with glucagon like peptide 2
ES2894629T3 (es) 2017-06-16 2022-02-15 Zealand Pharma As Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
WO2019072963A1 (en) 2017-10-12 2019-04-18 University Of Copenhagen POLYTHERAPY FOR THE TREATMENT OF BONE DISEASES
EP3699187A1 (de) 2019-02-21 2020-08-26 Universite D'angers Peptid zum targeting von gip und glp-2 rezeptoren zur behandlung von knochenerkrankungen
US20210187077A1 (en) * 2019-12-23 2021-06-24 Idaho State University GLP-1 Agonist Conjugates for Sustained Glycemic Control
CN115052619A (zh) * 2019-12-24 2022-09-13 韩美药品株式会社 包含glp-2或其缀合物的用于预防或治疗代谢性骨病的药物组合物
WO2022065898A1 (ko) * 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물
US12599544B2 (en) 2024-05-09 2026-04-14 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2583257B2 (ja) 1986-05-05 1997-02-19 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン向性ホルモン
ATE193541T1 (de) 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5512459A (en) 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DK1975177T3 (da) * 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
EP0906338B1 (de) 1996-04-12 2002-11-06 1149336 Ontario Inc. Analoge des glucagon ähnlichen peptides -2
DK0909312T3 (da) 1996-07-05 2003-03-17 Novo Nordisk As Fremgangsmåde til fremstilling af polypeptider
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
AU4112497A (en) 1996-08-30 1998-03-19 Novo Nordisk A/S Glp-2 derivatives
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DK1012186T3 (da) 1996-12-06 2002-11-04 Amgen Inc Keratinocyt-vækstfaktorer og anvendelser deraf
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
US6077949A (en) 1996-12-13 2000-06-20 Allelix Biopharmaceuticals, Inc. Cloned glucagon-like peptide 2 receptors
ATE358682T1 (de) 1996-12-13 2007-04-15 Allelix Biopharma Klonierte rezeptoren des glukagon-ähnlichen peptids-2
ES2210756T3 (es) * 1997-05-16 2004-07-01 1149336 Ontario Inc. Utilizacion de agonistas del glp-2 para mejorar el funcionamiento del tracto gastrointestinal superior.
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
AU8671798A (en) 1997-07-30 1999-02-22 Betagene, Inc. Methods and compositions relating to no-mediated cytotoxicity
ATE273996T1 (de) 1997-09-12 2004-09-15 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
WO1999037793A1 (en) 1998-01-23 1999-07-29 Novo Nordisk A/S Process for making desired polypeptides in yeast
EP2823812A1 (de) 1998-02-02 2015-01-14 Trustees Of Tufts College Dipeptidylpeptidase-IV-Hemmer zur Behandlung von Typ-II Diabetes
JP2002504527A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU7421598A (en) 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
CA2339537A1 (en) 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity
US6193997B1 (en) 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
WO2000034331A2 (en) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
PL205713B1 (pl) * 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
GB9905416D0 (en) 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1076066A1 (de) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptide zur Senkung des Blutglukosespiegels
WO2001041779A2 (en) 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
PT1695983E (pt) * 2000-06-16 2009-05-05 Lilly Co Eli Análogos do peptídeo-1 do tipo glucagon
EP1305338A2 (de) * 2000-08-02 2003-05-02 Theratechnologies Inc. Modifizierte peptide mit erhöhter wirksamkeit
WO2002022151A2 (en) * 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Also Published As

Publication number Publication date
EP1326630A2 (de) 2003-07-16
US6943151B2 (en) 2005-09-13
EP1970072A1 (de) 2008-09-17
JP5189723B2 (ja) 2013-04-24
ES2310192T3 (es) 2009-01-01
WO2002022151A2 (en) 2002-03-21
WO2002024214A3 (en) 2004-02-19
ES2345874T3 (es) 2010-10-05
US20040082507A1 (en) 2004-04-29
CY1110721T1 (el) 2015-06-10
CY1108263T1 (el) 2014-02-12
ATE396738T1 (de) 2008-06-15
US20020037836A1 (en) 2002-03-28
WO2002024214A2 (en) 2002-03-28
EP1414486A2 (de) 2004-05-06
PT1326630E (pt) 2008-09-02
EP1414486B1 (de) 2010-05-05
JP5161412B2 (ja) 2013-03-13
US6770620B2 (en) 2004-08-03
AU2002213925A1 (en) 2002-03-26
AU2001287892A1 (en) 2002-04-02
DE60142084D1 (de) 2010-06-17
WO2002022151A3 (en) 2003-03-13
EP1326630B1 (de) 2008-05-28
PT1414486E (pt) 2010-07-21
DK1414486T3 (da) 2010-08-30
DE60134251D1 (de) 2008-07-10
JP2004524268A (ja) 2004-08-12
DK1326630T3 (da) 2008-09-15
JP2004508410A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
DE60142084D1 (de) Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
ATE284172T1 (de) Steuerbare schlaufenstrukturen zur unterstützung von diagnostischen und therapeutischen elementen in kontakt mit körpergewebe
DE69932510D1 (de) Vaskularisierungsinhibitoren
PT1333887E (pt) Metodo de tratamento de desordens musculares
DE60230635D1 (de) Körperpflegeprodukte mit elastomeren bereichen, welche einen antimikrobiellen wirkstoff enthalten
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
UY27186A1 (es) Formulación farmacéutica
AU2002339128A1 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
IL172396A0 (en) Replikin peptides and uses thereof
NO20013004L (no) Anvendelse av biokjemiske substanser i en sammensetning for forhindringen og behandlingen av helsetilstander forårsaket avkonstriksjon av glattmuskelceller i organer i det menneskeligelegemet
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
ATE325122T1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
EP1301209A4 (de) Hyaluronan als cytotoxisches mittel, medikamenten-vor-sensibilisator und chemo-sensibilisator in der behandlung von krankheiten
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
IT1305313B1 (it) 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
Club et al. Autism Spectrum Disorders
ITBO930059A0 (it) Procedimento per ottenere la rigenerazione dei tessuti nella terapia odontoiatrica parodentale.
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
IL155853A0 (en) Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414486

Country of ref document: EP